A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
We are doing this study because we want to find out if ipatasertib in combination with paclitaxel (a common type of chemotherapy) is a better treatment for your type of breast cancer than paclitaxel alone.
Breast Cancer, Hormones
Triple-negative breast cancer (TNBC) or hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) that has spread.
Confirmation eligibility through testing of tumor tissue or blood.
18 - 120
Healthy Volunteers Needed
Duration of Participation
Up to 53 months, including follow up time.
OHSU Knight Cancer Institute Clinical Trials Info Line:
F. Hoffmann-La Roche Ltd.